Jim Cramer, the host of Mad Money, recently highlighted a surge in merger activity, pointing out that we’ve seen a significant uptick in deals over the past few days. He explained that this wave of mergers and acquisitions aligns with what he’s been predicting, a shift in M&A activity due to the change in administration.

JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.

For this article, we compiled a list of 12 stocks that were discussed by Jim Cramer during the episode of Mad Money on January 10. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the third quarter of 2024, which was taken from Insider Monkey’s database of 900 hedge funds.

CNBC’s Jim Cramer stresses the importance of investing for the long term, highlighting healthcare stocks Eli Lilly, Merck and Regeneron.

Mad Money' host Jim Cramer talks what he is seeing out the the JPMorgan healthcare conference. Gavin Newsom Halts Ronald Reagan's Environmental Law As a travel planner, I rarely recommend Paris or Rome.